Role of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction

Cell Death and Disease

Volumn 4, Issue 4, 2013, Pages

  Mitra, A ^a   Basak, T ^b   Datta, K ^a   Naskar, S ^a   Sengupta, S ^b   Sarkar, S ^a  

^a UNIVERSITY OF CALCUTTA   (India)

^b NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

crystallin B; Cardiac hypertrophy; Cardiomyocyte apoptosis; Myocardial infarction

Indexed keywords

ALPHA CRYSTALLIN; GLUCOSE REGULATED PROTEIN; TAUROURSODEOXYCHOLIC ACID; VOLTAGE DEPENDENT ANION CHANNEL 1; GLUCOSE REGULATED PROTEIN 78; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL ORGANELLE; CELL STRESS; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONTROLLED STUDY; HEART MITOCHONDRION; HEART MUSCLE NECROSIS; MALE; MOLECULAR DYNAMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT; REGULATORY MECHANISM; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARDIOMEGALY; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; HEAT-SHOCK PROTEINS; MALE; MITOCHONDRIA; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TAUROCHENODEOXYCHOLIC ACID; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 84879707253     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.114     Document Type: Article

References (58)

1. Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012; 15: 241-249
2. Smith RA, Duffy SW, Tabar L. Breast cancer screening: The evolving evidence. Oncology (Williston Park) 2012; 26: 471-475, 479-481, 485-486
3. Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95: 1056-1061
4. Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem 2010; 18: 1658-1671
5. Saunders LR, Verdin E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26: 5489-5504
6. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab 2008; 7: 104-112
7. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci 2007; 32: 555-560
8. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA 2006; 103: 10230-10235
9. Schlicker C, Gertz M, Papatheodorou P, Kachholz B, Becker CF, Steegborn C. Substrates and regulation mechanisms for the human mitochondrial sirtuins Sirt3 and Sirt5. J Mol Biol 2008; 382: 790-801
10. Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010; 17: 41-52
11. Warburg O. On the origin of cancer cells. Science 1956; 123: 309-314
12. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209: 211-215
13. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26: 877-890
14. Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol 2005; 70: 363-374
15. Pedersen PL. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg Effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007; 39: 211-222
16. Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: Mapping the site of binding. J Biol Chem 2008; 283: 13482-13490
17. Shoshan-Barmatz V, Keinan N, Zaid H. Uncovering the role of VDAC in the regulation of cell life and death. J Bioenerg Biomembr 2008; 40: 183-191
18. Liu W, Mu R, Nie FF, Yang Y, Wang J, Dai QS et al. MAC-related mitochondrial pathway in oroxylin-A-Induced apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 2009; 284: 198-207
19. Lu Z, Lu N, Li C, Li F, Zhao K, Lin B et al. Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 2012; 209: 211-220
20. Yang Y, Hu Y, Gu HY, Lu N, Liu W, Qi Q et al. Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 2008; 60: 1459-1463
21. Furtado CM, Marcondes MC, Sola-Penna M, de Souza ML, Zancan P. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLOS One 2012; 7: E30462
22. Penso J, Beitner R. Clotrimazole and bifonazole detach hexokinase from mitochondria of melanoma cells. Eur J Pharmacol 1998; 342: 113-117
23. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: A key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002; 1555: 14-20
24. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008; 40: 171-182
25. Shulga N, Wilson-Smith R, Pastorino JG. Sirtuin-3 deacetylation of cyclophilin D induces dissociation of hexokinase II from the mitochondria. J Cell Sci 2010; 123: 894-902
26. Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol 2002; 158: 647-657
27. Cooper HM, Huang JY, Verdin E, Spelbrink JN. A new splice variant of the mouse SIRT3 gene encodes the mitochondrial precursor protein. PLOS One 2009; 4: E4986
28. Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD-dependent histone deacetylase that translocates to the mitochondria upon cellular stress. Genes Dev 2007; 21: 920-928
29. Chiara F, Castellaro D, Marin O, Petronilli V, Brusilow WS, Juhaszova M et al. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLOS One 2008; 3: E1852
30. Machida K, Ohta Y, Osada H. Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J Biol Chem 2006; 281: 14314-14320
31. Denu JM. Vitamin B3 and sirtuin function. Trends Biochem Sci 2005; 30: 479-483
32. Vieira HL, Haouzi D, El Hamel C, Jacotot E, Belzacq AS, Brenner C et al. Permeabilization of the mitochondrial inner membrane during apoptosis: Impact of the adenine nucleotide translocator. Cell Death Differ 2000; 7: 1146-1154
33. Aniya Y, Imaizumi N. Mitochondrial glutathione transferases involving a new function for membrane permeability transition pore regulation. Drug Metab Rev 2011; 43: 292-299
34. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009; 61: 1250-1275
35. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007; 274: 1393-1418
36. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25: 4777-4786
37. Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 2006; 25: 4683-4696
38. Rosano C. Molecular model of hexokinase binding to the outer mitochondrial membrane porin (VDAC1): Implication for the design of new cancer therapies. Mitochondrion 2011; 11: 513-519
39. Goldin N, Arzoine L, Heyfets A, Israelson A, Zaslavsky Z, Bravman T et al. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008; 27: 4636-4643
40. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403: 795-800
41. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417-435
42. GorospeM, de Cabo R. AsSIRTing the DNA damage response. Trends Cell Biol 2008; 18: 77-83
43. Guarente L, Picard F. Calorie restriction -The SIR2 connection. Cell 2005; 120: 473-482
44. Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol 2003; 38: 1065-1070
45. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011; 19: 416-428
46. Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2010; 117: 1670-1678
47. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15: 1406-1418
48. Korzick DH, Kostyak JC, Hunter JC, Saupe KW. Local delivery of PKCepsilon-Activating peptide mimics ischemic preconditioning in aged hearts through GSK-3beta but not F1-ATPase inactivation. Am J Physiol Heart Circ Physiol 2007; 293: H2056-H2063
49. Wei L, Lu N, Dai Q, Rong J, Chen Y, Li Z et al. Different apoptotic effects of wogonin via induction of H(2)O(2) generation and Ca(2) overload in malignant hepatoma and normal hepatic cells. J Cell Biochem 2010; 111: 1629-1641
50. Kachadourian R, Day BJ. Flavonoid-Induced glutathione depletion: Potential implications for cancer treatment. Free Radic Biol Med 2006; 41: 65-76
51. Pereira CV, Lebiedzinska M, Wieckowski MR, Oliveira PJ. Regulation and protection of mitochondrial physiology by sirtuins. Mitochondrion 2011; 12: 66-76
52. Smith BC, Hallows WC, Denu JM. Mechanisms and molecular probes of sirtuins. Chem Biol 2008; 15: 1002-1013
53. Hafner AV, Dai J, Gomes AP, Xiao CY, Palmeira CM, Rosenzweig A et al. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging 2010; 2: 914-923
54. Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-Interacting drugs: From cell death to lifespan extension. Trends Pharmacol Sci 2005; 26: 94-103
55. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107: 137-148
56. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: A review. Mol Pharmacol 2005; 68: 917-932
57. Li HB, Chen F. Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 2005; 1074: 107-110
58. Zhao L, Guo QL, You QD, Wu ZQ, Gu HY. Gambogic acid induces apoptosis and regulates expressions of Bax and Bcl-2 protein in human gastric carcinoma MGC-803 cells. Biol Pharm Bull 2004; 27: 998-1003